📌In our December issue
Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression
Read it here👉https://t.co/vrXquPNSOU
@docberza#LiverTwitter
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
#OpenAccess here👉https://t.co/ZghyEO4Pwu
#LiverTwitter
Agile scores in MASLD and ALD
➡️External validation and their utility in clinical algorithms
Full text here👉https://t.co/5gnEdQBs3d
@marg_p#LiverTwitter
NEW PRACTICE GUIDANCE
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases
#LiverTwitter
https://t.co/vYtaF0vcdh
Hartmann P et al. Prevalencia global y nacional de la enfermedad del hígado graso no alcohólico en adolescentes: un análisis del estudio de carga global de enfermedad 2019
#LiverTwitter
https://t.co/jnPse5alIH
📢New nomenclature & diagnostic criteria for #fattyliverdisease agreed by global consensus❗️
➡️#MASLD: metabolic dysfunction-associated steatotic liver disease
✅non-stigmatising
✅can improve awareness & patient identification
🔓#OpenAcces👉https://t.co/PlTfC3XWQ4